The species is Spirulina (Arthrospira platensis), specifically for its phycocyanin content — the only commercially available natural blue pigment at scale. The reasoning: phycocyanin is a protein-pigment complex unique to cyanobacteria and red algae; Spirulina is the only organism currently produced at industrial scale that contains it; it is already EU-approved as a natural food colourant (E6 designation) and used in products like M&Ms and blue sports drinks. It produces a vibrant cyan-blue that has no natural competitor at comparable cost and scale. Key commercial risks: (1) Stability — phycocyanin degrades rapidly with heat, light, and acidic pH. It cannot be used in products that require pasteurisation, acidic formulations (pH below 4), or long ambient shelf life without encapsulation technology. This is a real formulation challenge. (2) Price — food-grade phycocyanin currently costs $500–1,500/kg, vs synthetic Blue #1 at roughly $20–50/kg. The EU ban creates demand, but food manufacturers will resist large cost increases unless they can justify it with "natural" positioning that consumers will pay for. (3) Quality consistency — phycocyanin content varies between Spirulina batches and producers; colour intensity can fluctuate. Supply chain reliability and standardisation are critical for food manufacturers requiring consistent colour. The strategic opportunity: companies that can stabilise phycocyanin (through encapsulation, microencapsulation, or spray drying optimisation) and supply it at consistent purity will capture significant value as the EU transition accelerates through the late 2020s.

Company A (natural) has a stronger long-term competitive position for the following reasons: First — regulatory differentiation. In most major salmon-consuming markets (EU, US, Japan), labelling regulations require disclosure of synthetic astaxanthin on product labels. An increasing number of premium salmon buyers (Whole Foods, major European retailers) mandate natural astaxanthin only. This creates a protected market segment that synthetic cannot access regardless of price. Second — biological efficacy. The natural 3S,3'S isomer from Haematococcus has approximately 20× greater antioxidant activity than the racemic synthetic mixture. In salmon, this means better flesh colour per unit dose, better immune function, and lower feed conversion ratios for the pigmentation outcome — a genuine performance advantage, not just a label claim. Third — consumer and regulatory trajectory. ESG pressures and consumer preference trends are moving systematically away from petrochemical-derived additives in food production. This trend is unlikely to reverse. The regulatory risk is overwhelmingly on the synthetic side, not the natural. The counter-argument: Company A has much higher production costs ($1,500–3,000/kg vs ~$800–1,500/kg synthetic) and slower production timelines. Company A is only viable if it can sell at a premium sufficient to cover the cost gap — and if that premium market is large enough to absorb its production capacity. In Hawaii's high-cost environment, breakeven economics require a selling price that may be 2–3× synthetic. The key question is whether the premium market (natural-only salmon aquaculture) is large enough and growing fast enough to support Company A's cost structure. If yes — Company A wins. If natural certification in aquaculture fails to achieve mainstream adoption within 5–7 years, Company A faces serious margin pressure.

The answer lies in each species' natural ecological niche and the contamination selectivity it provides. Dunaliella salina evolved in hypersaline environments where salt concentration reaches 10–30% — conditions lethal to virtually all other organisms, including competing algae, fungi, bacteria, and grazers. When you grow Dunaliella in 15–25% salt water in an open pond, the saline environment itself is the sterilisation system. No other organism can establish and outcompete Dunaliella at these salinities. This allows massive, cheap, unlined open ponds — essentially large shallow salt evaporation ponds — with minimal contamination management. The Australian facility at Hutt Lagoon works precisely because coastal desert + hypersaline water + intense sun creates exactly the conditions Dunaliella dominates in nature. Haematococcus, by contrast, evolved in temporary freshwater rock pools — a very different environment. It is slow-growing (doubling time of 2–4 days vs Dunaliella's faster rate) and grows in ordinary freshwater conditions (low salinity, moderate pH, no extreme chemistry). In an open pond, any faster-growing contaminating alga — Chlorella, Scenedesmus, Chlamydomonas — will outcompete it within days. Bacterial biofilms form on surfaces. Rotifers (microscopic animals) graze on cells. None of Dunaliella's competitive moats (extreme salinity) apply to Haematococcus's culture conditions. This is why Phase 1 (growth) must be conducted in closed, often sterile photobioreactors where contamination is physically excluded rather than ecologically prevented. The biology of natural habitat directly determines the commercial production infrastructure required — and therefore the capital cost of the facility.

Harvesting is one of the largest cost components in algae production — typically 20–40% of total production cost — and cell size is the primary determinant of harvesting method and cost. Spirulina's helical filaments are 300–500 μm long — visible to the naked eye and easily captured by simple mesh screen filtration. A filter with 50–100 μm mesh holes will retain virtually all Spirulina while letting the culture water pass through. This can be done with simple, cheap, low-energy belt filters or drum filters. Operating cost is minimal. Capital cost is low. Nannochloropsis cells at 2–5 μm are far below the threshold for any mesh filtration — they pass through all practical filters. The only methods that work for such small cells are: (1) Centrifugation — spinning the culture at high G-force to pellet cells. Effective but extremely energy-intensive (typically 1–3 kWh per kg of biomass harvested) and expensive capital equipment. (2) Flocculation — adding chemicals (or using bioflocculation, electrocoagulation) to aggregate cells into larger clumps that settle by gravity. Cheaper but adds chemical cost and may contaminate the product. (3) Dissolved air flotation — bubbling air through the culture to float aggregated cells. Used for some species. The energy cost of centrifuging Nannochloropsis vs filtering Spirulina is estimated to be 10–30× higher per unit of biomass. For a high-value product like EPA or astaxanthin this cost is absorbable. For lower-value products like bulk biomass for feed, the harvesting cost alone can make Nannochloropsis production economically unviable. This single biological parameter — cell size — is why Spirulina dominates bulk commodity markets and Nannochloropsis stays in higher-margin applications. Engineering larger Nannochloropsis cells, or discovering efficient low-cost aggregation methods, remains an active research area with significant commercial value.

Model answer — Nannochloropsis for EPA in aquaculture feed replacement: The opportunity: wild-catch fishmeal omega-3s (anchovy, herring) supply ~70% of EPA/DHA used in global salmon aquaculture. Wild fish stocks are declining; catch limits are tightening; sustainability certification bodies (ASC, BAP) are raising requirements. Nannochloropsis is the leading candidate to replace fishmeal-derived EPA because it is already produced commercially for marine hatcheries, has the most advanced genetic engineering toolkit of any microalga, and multiple companies (notably Veramaris, a DSM-Evonik joint venture) have proven the commercial viability of algae-derived EPA for salmon feed at scale. The addressable market for EPA in salmon feed alone exceeds $1B/year and is growing with aquaculture expansion. A company that can reduce Nannochloropsis EPA production cost by 30–50% through improved strains, cultivation optimisation, or better harvesting has a very large addressable market with favourable regulatory and ESG tailwinds. Three critical biological/technical risks that could invalidate this thesis: Risk 1 — Harvesting cost ceiling. Nannochloropsis's 2–5 μm cell size means centrifugation dominates harvesting cost. If no breakthrough in cheap aggregation/flocculation method emerges, the cost floor for Nannochloropsis biomass may be structurally too high for the feed market (which has thin margins). Even with strain improvement, the physics of centrifuging tiny cells at industrial scale imposes a cost floor that synthetic competitors do not face. Risk 2 — EPA fraction erosion under scale-up. In lab conditions, EPA content of 35% of fatty acids is achievable. In outdoor commercial ponds with variable light, temperature, and CO₂, EPA fraction often drops to 15–25%. Strain performance in commercial conditions consistently underperforms lab benchmarks — the "scale-up gap." If engineered strains that perform excellently in the lab regress to wild-type EPA content at outdoor scale, the economic model breaks. Risk 3 — Genetic stability over production runs. CRISPR-engineered strains that overexpress EPA biosynthesis enzymes may experience evolutionary pressure to revert or silence the inserted genes over extended production runs. Algae reproduce rapidly — any mutation that reduces the metabolic cost of overproducing EPA will spread through the population within weeks. Maintaining genetic integrity of engineered strains through months-long commercial production runs without sterile conditions is a known and unsolved challenge for the field.